Loading...
Next-generation proteasome inhibitors for cancer therapy
Over two decades ago, the proteasome was considered a risky or even untenable therapeutic target. Today proteasome inhibitors are a mainstay in the treatment of multiple myeloma (MM) and have sales in excess of three billion US dollars annually. More importantly, the availability of proteasome inhib...
Na minha lista:
| Udgivet i: | Transl Res |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6151281/ https://ncbi.nlm.nih.gov/pubmed/29654740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trsl.2018.03.002 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|